Alan Burnett
Prosiectau fel Prif Ymchwiliwr
- AML 16 being a National Cancer Research Institute Acute Myeloid Leukaemia and High Risk MDS Trial (06.08.2010 - 31.07.2013)
- AML17: A trial of development of the Myeloid Leukaemia and high risk Myelodysplastic Syndrome in younger patients (01.08.2008 - 31.07.2014)
- AML 17 being an acute myeloid leukaemia or high risk myelodysplastic syndrome multi-site randomised trial (01.02.2009 - 31.01.2012)
- AML 18 pilot (23.05.2011 - 22.11.2012)
- A phase 1B/2 study to evaluate the feasibility of combining either the tyrosine kinase inhibitor AC220 or the CXCR4 inhibitor Plerixafor with chemotherapy in older patients with acute myeloid leukaemia and myelodysplastic syndrome in patients over 60 (01.06.2011 - 31.12.2013)
Prosiectau fel Cyd-Ymchwiliwr
- Role of OGG1 in the pathogenesis of acute myeloid leukaemia (01.04.2009 - 30.09.2011)
- Targets for treatment in AML: Discovery and translation (01.04.2010 - 19.09.2013)
- Targets for treatment in AML: Discovery and translation (20.09.2013 - 01.12.2015)
- Use of microarray to identify the mechanism of developmental disruption induced by over-expression of g-catenin in AML (01.02.2008 - 31.07.2009)
- Wales Cancer Trials Network (01.09.2004 - 31.08.2009)